Ask AI
ProCE Banner Series

Precision Pathways in RCC: Translating Immunotherapy and Targeted Therapy Advances Into Personalized Patient Care

The symposium will feature experts in renal cell carcinoma (RCC) discussing the current treatment landscape to deepen understanding of emerging immunotherapy and targeted therapies, improve personalization, and prepare teams for next-generation care integration.

Not an official event of the 2026 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.

  AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This activity is for oncologists, advanced practitioners, nurse practitioners, clinical nurse specialists, pharmacists, physician associates, and other healthcare professionals caring for patients with renal cell carcinoma. 

All Events

Precision Pathways in RCC: Translating Immunotherapy and Targeted Therapy Advances Into Personalized Patient Care

Upcoming Events

May

29

2026

6:30 PM - 9:00 PM Central Time (CT)

In-personVirtual

Hilton Chicago, 720 S Michigan Ave, Chicago, Illinois 60625

Topics

Renal Cell Carcinoma

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
This activity aims to improve learners’ knowledge, confidence, and clinical competence in applying the latest evidence from pivotal and emerging trials of immunotherapy and targeted agents to optimize treatment sequencing, biomarker-guided selection, and TRAE management in RCC.

Target Audience
This activity is for oncologists, advanced practitioners, nurse practitioners, clinical nurse specialists, pharmacists, physician associates, and other healthcare professionals caring for patients with renal cell carcinoma. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Stratify RCC patients’ benefit likelihood from IO- or targeted regimens based on validated clinical, molecular, and tumor microenvironment biomarkers as well as traditional risk assessment

  • Plan patient-centric first- and subsequent-line therapy for advanced/metastatic RCC using up-to-date guidelines, prior therapy history, evolving biomarker insights, and practical administration considerations

  • Manage adverse events across all approved and emerging systemic RCC regimens, considering regimen-specific toxicity, patient comorbidities, and optimal supportive care strategies

  • Evaluate current and emerging data from key clinical trials and real-world evidence for new targeted, immunotherapy, and cellular therapy strategies in both clear cell and non-clear cell RCC, and advocate for clinical trial participation where appropriate.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 2.0 contact hours.

Continuing Pharmacy Education

Clinical Care Options, LLC dba Decera Clinical Education designates this continuing education activity for 2.0 contact hours (0.20 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: xxxx

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification 

 
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

For ABIM MOC points, your information will be shared with the ABIM through Decera Clinical Education’s Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records. 

By sharing your Diplomate Board ID # and DOB, you are giving Decera Clinical Education permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS). 

IPCE Credit Designation

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/657115052be04.jpg

This activity was planned by and for the healthcare team, and learners will receive 2.0 Interprofessional Continuing Education (IPCE) credits for learning and change.

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by educational grants from AVEO Pharmaceuticals, Inc., Bristol Myers Squibb, Eisai Inc., and Merck Sharp & Dohme LLC.

AVEO Pharmaceuticals, Inc.

Bristol Myers Squibb

Eisai Inc.

Merck Sharp & Dohme LLC

For customer support please click here.

Mailing Address:

 

Decera Clinical Education
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191